November 5, 2020

Novocure Announces Closing of $575 Million 0% Convertible Senior Notes Private Placement

Initial conversion price represents a premium of approximately 50% ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company striving to extend survival in some of the most aggressive forms of cancer, today announced the closing of its previously announced offering of $575 million aggregate principal amount of… Read More
learn more
November 2, 2020

Novocure Prices $500 Million 0% Convertible Senior Notes Private Placement

Initial conversion price represents a premium of approximately 50% ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR), a global oncology company striving to extend survival in some of the most aggressive forms of cancer, today announced the pricing of $500 million aggregate principal amount of its 0% Convertible Senior Notes due… Read More
learn more
November 2, 2020

Novocure Announces Proposed Private Placement of $500 Million of Convertible Senior Notes

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a global oncology company striving to extend survival in some of the most aggressive forms of cancer, today announced its intention to offer $500 million aggregate principal amount of Convertible Senior Notes due 2025 (the “notes”). The notes will be offered in a… Read More
learn more
October 29, 2020

Novocure Announces Strategic Alliance with NYU Grossman School of Medicine for Preclinical and Clinical Research

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today announced it has entered into a strategic alliance with the NYU Grossman School of Medicine’s Department of Radiation Oncology that provides a framework for preclinical and clinical development projects studying Tumor Treating Fields. Novocure’s Tumor Treating Fields are electric fields that disrupt… Read More
learn more
October 29, 2020

Novocure Reports Third Quarter 2020 Financial Results and Provides Company Update

Quarterly net revenues of $132.7 million, representing 44 percent growth versus the third quarter 2019 and 14 percent growth versus the second quarter 2020 Quarterly net income of $9.3 million with $0.09 in earnings per share ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) today reported financial results for… Read More
learn more
October 2, 2020

Novocure to Report Third Quarter 2020 Financial Results

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will report financial results for the third quarter 2020 on Thursday, October 29, 2020, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the three and nine… Read More
learn more
September 29, 2020

Novocure to Host Virtual Research & Development Day

Novocure’s virtual Research & Development Day on November 12 will highlight progress across clinical and developmental pipelines and introduce areas of focus in translational research ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will host a virtual Research & Development Day for analysts and investors… Read More
learn more
September 25, 2020

Novocure Honors Mesothelioma Day with Activities to Raise Awareness of Mesothelioma and Support the Community

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today initiatives to bring attention to Mesothelioma Awareness Day on September 26. In partnership with the Mesothelioma Applied Research Foundation, Novocure has arranged for 25 buildings and landmarks to be lit in blue, the color associated with mesothelioma awareness. In 18 cities… Read More
learn more
September 4, 2020

Novocure to Participate in the 2020 Wells Fargo Virtual Healthcare Conference

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that William Doyle, the company’s Executive Chairman, and Dr. Uri Weinberg, the company’s Chief Science Officer, will participate in the 2020 Wells Fargo Virtual Healthcare Conference on September 9, 2020. Mr. Doyle and Dr. Weinberg will take part in a… Read More
learn more
August 13, 2020

Novocure Announces Expansion of Its Executive Leadership Team

Wilco Groenhuysen appointed to an expanded Chief Operating Officer role Ashley Cordova promoted to Chief Financial Officer Frank Leonard promoted to Chief Development Officer ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ:NVCR) today announced an expansion of its Executive Leadership Team, effective Sept. 1, 2020, intended to further solidify… Read More
learn more